

Experience of using the drug Fuzailova
B.N. Fuzailov, S.K. Makina
(Moscow, Russia; Petropavlovsk, Kazakhstan)

In clinical oncological practice, since 1990, the drug "MR - anti-protein blocker", developed by BN Fuzailov, has been used. based on the hypothesis of a single mechanism for the nucleation of a cancer cell. The drug prevents the combination of lactic acid with phenylalanine, the formation of a complex highly polar compound bond, the development of further processes and returns the malignant cell to the normal path of obtaining energy from glycogen. The oncological cell receives nutrition due to the breakdown of glucose, switches to the ancient path of energy production: anaerobic glycolysis.

Since November 2005, when examining the patients who applied, all were tested for the need to use the drug Fuzailova (PF). The study of patients was carried out using a vegetative resonance test (ART) on a hardware-software complex (AIC) "IMEDIS-EXPERT" Center "IMEDIS" (Moscow). A total of 86 patients were examined. Of these, 29 (100%) patients - 22 women (76%) and 7 men. (24%) gave a resonant response to IF in the following clinical cases:

1. Malignant processes of various localization, identified by the method of vegetative resonance test - 4 cases. All patients are monitored at the oncological dispensary. In all cases, the oncoprotein test is positive, the photon index (PI) is 21/22, the biological index (BI) is 21, the shift in metabolism towards anabolism is 5-6 tbsp. Psora miasm - 3 cases, sycosis - 1.

2. Hepatitis C - 5 cases. In 4 cases, the diagnosis was verified biochemical blood tests, PCR. Oncoprotein test is positive in 1 case. FI - 20/21, BI - 18/21. Shift of metabolism towards catabolism and alkalinity. Psora miasm - 4 cases, sycosis - 1.

3. Benign processes of various localization - 9 cases. Female patients. 7 of them were examined by an oncologist and a gynecologist. Oncoprotein test is positive in 3 cases. FI in the 1st case 22. In general, FI, BI, RA were not alarming. Psora miasm - 6 cases, sycosis - 2, luezinum - 1.

4. Dysbacteriosis of the large intestine - 3 cases. Oncoprotein test negative. FI - 21/22, BI - 15/18/21. Psora miasm - 2 cases, sycosis - 1.

5. Autoimmune thyroiditis - 1 case. "Oncoprotein" will put it down; FI - 3, BI - 4. Miasm - sycosis.

6. Condition after hysterectomy along the pod of uterine fibroids - 2 cases. "Oncoprotein" pos.; in 1 case; FI - 21/22, BI - 18/19. Psora miasm - 2 cases.

7. Chroniosepsis (*Pseudomonas aeruginosa*, Epstein-Barr virus) - 2 cases. "Oncoprotein" pos. - 1 case, neg. - 1. FI - 21/22. Psora miasm - 1 case, luezin - 1.

8. Chr. gastritis - 2 cases. "Onkobelok" - neg. FI - 21/22, BI - 20/21. Psora miasm - 2 cases. The key infection is *Helicobacter*.

9. Chronic bronchitis - 1 case. "Onkobelok" otrits. BI - 19, FI - 20. The key infection is *Helicobacter*. Miasm is psora.

The largest proportion of cases, response to PF in the age group

31–40 years old - 8 (27.8%), 41–50 years old - 9 (31%).

The oncoprotein test was positive in 11 cases (37.9%). The test correlates with low PI, BI.

Oncoprotein test was negative in 10 cases (34.4%) against the background of low PI, BI in patients diagnosed with hepatitis C, large intestine dysbacteriosis; condition after hysterectomy for uterine fibroids; chroniosepsis; diseases where the key infection is tested

Helicobacter.

Oncoprotein test negative. against the background of indifferent indicators of FI, BI in 7 cases (24.1%) in patients with benign formations.

The psora miasm was detected in 21 cases (72.4%); sycosis - 6 (20.6%); luezin - 2 (6.9%).

Adaptive bioresonance and multiresonance therapy was carried out at the IMEDIS EXPERT agro-industrial complex of the IMEDIS Center. Drainage preparations were selected. The principle of the mismatic approach to solving the problem was observed. Prescribed psorinum, gonococcinum, luezinum in potency C100-200 and higher, according to the tests.

No other drugs of chemical origin were prescribed to patients. Fuzailov's drug was tested through Ferrum met. D60 + key organ + indicators of impaired metabolism. The dose of the drug was determined through the optimal adaptation reserves. On the recommendation of B.N. Fuzailov. the found spectrum of potencies of PF was transferred to sugar crumbs; hemodez solution 200-400 ml, within 10 minutes. At the same time, 2 ml of venous blood was taken from the patient, to which the information of the tested PF was transferred for 5 minutes, followed by intramuscular injection. Control testing of PF was carried out at each repeated admission. In the case when a new pathophysiological chain resonated with PP in a certain spectrum of potencies, the drug was re-administered. One session was carried out for 2-3 hours.

As a result of complex therapy, in 23 cases (79.3%), a clear positive effect was observed, manifested in a decrease in the size and degree of density of formations, a significant regression of intoxication syndrome, positive dynamics of laboratory tests, as well as ART indicators. In three cases of therapy of patients with hepatitis C who have undergone insufficiently effective therapy by methods of orthodox medicine, there is a clear normalization of biochemical and virological data.

In 1 case (3.4%), a patient with a malignant process had no positive effect.

The patient interrupted the treatment after 2 sessions.

In 2 cases (6.9%) - a moderate positive effect in patients with chronic gastrointestinal diseases. The key infection is *Helicobacter*. In 3 cases, therapy has just begun.

The observations continue.

Conclusions:

1. A positive test of the drug Fuzailova gives indirect information about the degree of concentration of lactic acid (MK) and phenylalalanine (FA), about

the degree of readiness to create methylalanine (MA), thereby showing both borderline states and obvious malignant changes in the human body.

2. Positive test "oncoprotein" correlated with integrative indicators of ART, a positive resonant response to PF informs about an obvious malignant process.

3. A negative test "oncoprotein" must be interpreted against the background ART tests (low PI, BI, metabolic disorders in the direction of anabolism, etc.), but the presence of a resonant response to PF should alert the doctor in terms of cancer search and refer these patients to the risk group, when the borderline state with an increase in the concentration of MK and PA can suddenly go to malignant - into the state of MA synthesis.

4. Negative test "oncoprotein", indifferent parameters of ART, a positive resonance response to IF also indicates a threatening degree of concentration of MK and PA. All this allows us to attribute these patients to the risk group in terms of cancer incidence.

5. Thus, Fuzailov's drug must be used not only for therapy, but also as an additional tumor marker for identifying obvious, hidden, suspected malignant processes at individual appointments and during mass preventive examinations.

Literature

1. Abstracts and reports of international conferences "Theoretical and clinical aspects of the use of bioresonance and multiresonance therapy".

- M.: IMEDIS, 2002. Part I. - P. 199-204; with. 211; 2003; Part I. - P. 363-366.; 2004.

- Part II. Pp. 7-302; 2005. Part I. - S. 184-185.

2. Gotovsky Yu.I., Kosareva L.B., Sazonova I.M., Frolova L.A., Gritsenko E.G. Electropuncture diagnostics and therapy using the vegetative resonance test "IMEDIS-TEST": Methodical recommendations. - M.: IMEDIS, 2000.